Residents who suffer from Alzheimer’s Disease were dealt a significant blow. They, along with advocates in Iowa, are stunned over the decision by the Centers for Medicare and Medicaid Services, or CMS, to deny coverage for an entire class of drugs to treat Alzheimer’s disease. Lauren Livingston, spokeswoman for the Iowa Chapter of the Alzheimer’s Association, says the blanket decision has tremendous implications beyond the initial drug, Aduhelm.
The draft decision says all future FDA-approved treatments in this class of drugs, regardless of clinical trial results and what the FDA recommends, will not be covered except in another clinical trial.
Aduhelm is showing promise in the treatment of early-stage Alzheimer’s and for others with mild cognitive impairment. For CMS to deny coverage, Livingston says, is putting concerns about money over the lives of patients.